newswire, breaking biotechnology and pharma news

Tuesday, February 3, 2015

Recent Biotech IPO’s; (ASND), (ENTL), (FLKS), (ONCE), (TCON), (ZSAN)

Recent Biotech IPO’s; (ASND), (ENTL), (FLKS), (ONCE), (TCON), (ZSAN)

Point Roberts WA, NEW YORK, NY – February 3, 2015 -, a global news source covering leading sectors including biotech and medical technology stocks reports on the recent IPO’s in the sector. The flood of IPO’s is making experts ask if a biotech bubble is being created. With up to 100 IPO’s in the works for this year, time will tell.

Here is a look at some of the recent listings:

Ascendis Pharma (NASDAQ:ASND) completed its initial public offering of 6,900,000 American Depositary Shares (ADSs) at a price to the public of $18.00 per ADS. The stock is currently trading at $19.04. Ascendis Pharma A/S is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Entellus Medical Inc (NASDAQ:ENTL) began trading on The NASDAQ Stock Market on January 29, 2015. The IPO consisted of 4,603,580 shares of its common stock at an initial public offering price of $17.00 per share Entellus is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. The XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses. The stock is currently trading at $21.52.

On January 28th Flex Pharma Inc (NASDAQ: FLKS) announced its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share. Flex Pharma, Inc. is a biopharmaceutical company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions.

January 30th Spark Therapeutics Inc (NASDAQ:ONCE)  announced its offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts. Spark is a late clinical-stage gene therapy company seeking to develop one-time, life-altering treatments for debilitating genetic diseases, with an initial focus on treating rare diseases. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. The stock is trading at $45.82 this morning.

TRACON Pharmaceuticals Inc (NASDAQ:TCON) IPO consisted of 3,600,000 shares of common stock at a price to the public of $10.00 per share. TRACON develops targeted therapies for cancer, agerelated macular degeneration and fibrotic diseases. TRACON’s current pipeline includes two clinical stage product candidates: TRC105, an antiendoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. The stock is currently trading below its IPO price. 

Zosano Pharma Corp (NASDAQ:ZSAN) completed its offering of 4,500,000 shares of common stock at a price to the public of $11.00 per share. The stock is trading at $11.06 in this morning’s session. Zosano Pharma Corporation is a clinical stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver its proprietary formulations of existing drugs through the skin for the treatment of a variety of indications. Zosano's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections. Zosano's microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow on Twitter!/Investorideas
Follow on Facebook

Sign up for free news alerts at

Become an Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors  

Disclaimer/ Disclosure: The newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info:
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.


800 665 0411

No comments:

Post a Comment